



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (Substitute)	Attorney Docket Number NRNZ-1005US1	Application Number 10/606,574
	Applicant Owner: Gluckman et al.	
	Filing Date: June 26, 2003	
Information Disclosure Statement BY APPLICANT (Use several sheets if necessary)		

U.S. PATENTS					Class	Subclass
Examiner Initial	Patent Number	Issue Date	First Named Inventor			
JR	6,294,585	9/25/01	Brown	514	279	
JR	6,187,906	2/13/01	Gluckman, et al.	530	331	
JR	5,714,460	2/3/98	Gluckman, et al.	514	3	

U.S. PATENT PUBLICATIONS				
Examiner Initial	Application Number	Pub. date	First Named Inventor	
JR	2002/0035066 A1	3/21/2002 5/24/02	Gluckman et al	514 18

FOREIGN PATENT DOCUMENTS						
Examiner Initial	Document Number	Publication Date	Country	Class	Subclass	Trans-lation Yes No
JR	WO 98/14202	4/9/98	PCT			
JR	0 366 638 A2	2/5/90	EP0			
JR	WO 95/17204	6/29/95	PCT			

OTHER DOCUMENTS (Include author (if any), title, publisher and place of publication, date and pertinent pages)	
JR	Sara, Vicki R., et. al., "The Biological Role of Truncated Insulin-like Growth Factor-1 and the Tripeptide GPE in the Central Nervous System", Annals of the New York Academy of Sciences, 692, 1993, 183-191
JR	Sara, Vicki R., et. al., "Identification of Gly-Pro-Glu (GPE), the Aminoterminal tripeptide of insulin-like growth factor 1 which is truncated in brain, as a novel neuroactive peptide", Biochemical and Biophysical Research Communications, Vol. 165, No. 2, December 15, 1989, 766-771
JR	Saura, J., et. al., "Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro", NeuroReport, Vol. 10, No. 1, January 1999, 161-164
JR	Nilsson-Hakansson, Lena, et. al., "Effects of IGF-1, truncated IGF-1 and the tripeptide Gly-Pro-Glu on acetylcholine release from parietal cortex of rat brain", NeuroReport, Vol. 4, No. 9, August 1993 (September Issue), 1111-1114

Jeffrey E. Russell

September 16, 2004

- 3 -

10/606,574

OTHER DOCUMENTS (Include author (if any), title, publisher and place of publication, date and pertinent pages)	
<i>JR</i>	Ludecke et al., "Recessively inherited L-DOPA-responsive parkinsonism in infancy caused by point mutation (L205P) in the tyrosine hydrolyse gene", Hum. Gen. 102:644-646 (1998)
<i>JR</i>	Danks et al., "Tetrahydrobiopterin treatment of variant form of phenylketonuria", Lancet 2:1043, 1975
<i>JR</i>	Ludecke et al., "A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome", Hum. Gen. 93:123 (1995)
<i>JR</i>	Mallet, "Tyrosine hydroxylase from cloning to neuropsychiatric disorders", Brain Research Bulletin 50(5,6):381-382 (1999).
<i>JR</i>	Guan et al., "N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats", Brain research 2000, Mar 24 859(2), 286-92.
Examiner	Jeffrey E. Russell
	Date Considered September 16, 2004

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*1 = Copy not submitted because it was submitted in prior application SN /_____, filed _____, 20_____, relied on under 35 USC §120.
*2 = Copy not submitted because it was submitted in prior application SN /_____, filed _____, 20_____, relied on under 35 USC §120.